Oral factor Xa inhibitors in acute coronary syndromes

Luke Tapp; Ben Wrigley; Gregory Lip

doi:10.1038/nrcardio.2009.160

Oral factor Xa inhibitors in acute coronary syndromes

Luke Tapp, Ben Wrigley, Gregory Lip

Research output: Contribution to journal › Editorial

1 Citation (Scopus)

Abstract

Factor Xa inhibitors, a new class of oral anticoagulants, have been evaluated in the phase II ATLAS ACS-TIMI 46 and APPRAISE trials. addition of these agents to standard therapy has tended to reduce the incidence of adverse cardiovascular events at the expense of a dose-dependent increase in the risk of bleeding complications.

Original language	English
Pages (from-to)	619-620
Number of pages	2
Journal	Nature Reviews Cardiology
Volume	6
Issue number	10
DOIs	https://doi.org/10.1038/nrcardio.2009.160
Publication status	Published - 1 Oct 2009

Access to Document

10.1038/nrcardio.2009.160

Cite this

@article{b8f8f1e4e72843acad4f41a1c39c37b8,

title = "Oral factor Xa inhibitors in acute coronary syndromes",

abstract = "Factor Xa inhibitors, a new class of oral anticoagulants, have been evaluated in the phase II ATLAS ACS-TIMI 46 and APPRAISE trials. addition of these agents to standard therapy has tended to reduce the incidence of adverse cardiovascular events at the expense of a dose-dependent increase in the risk of bleeding complications.",

author = "Luke Tapp and Ben Wrigley and Gregory Lip",

year = "2009",

month = oct,

day = "1",

doi = "10.1038/nrcardio.2009.160",

language = "English",

volume = "6",

pages = "619--620",

journal = "Nature Reviews Cardiology",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Oral factor Xa inhibitors in acute coronary syndromes

AU - Tapp, Luke

AU - Wrigley, Ben

AU - Lip, Gregory

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Factor Xa inhibitors, a new class of oral anticoagulants, have been evaluated in the phase II ATLAS ACS-TIMI 46 and APPRAISE trials. addition of these agents to standard therapy has tended to reduce the incidence of adverse cardiovascular events at the expense of a dose-dependent increase in the risk of bleeding complications.

AB - Factor Xa inhibitors, a new class of oral anticoagulants, have been evaluated in the phase II ATLAS ACS-TIMI 46 and APPRAISE trials. addition of these agents to standard therapy has tended to reduce the incidence of adverse cardiovascular events at the expense of a dose-dependent increase in the risk of bleeding complications.

U2 - 10.1038/nrcardio.2009.160

DO - 10.1038/nrcardio.2009.160

M3 - Editorial

C2 - 19773793

VL - 6

SP - 619

EP - 620

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

IS - 10

ER -

Oral factor Xa inhibitors in acute coronary syndromes

Abstract

Access to Document

Fingerprint

Cite this